Cogent Biosciences ( NASDAQ:COGT – Get Rating ) had its price objective decreased by HC Wainwright from $28.00 to $27.00 in a research note published on Thursday morning, The Fly reports. A number of other equities research analysts have also recently commented on COGT. Guggenheim restated a buy rating and set a $26.00 target price on shares of Cogent Biosciences in a research report on Wednesday, March 15th. Robert W. Baird assumed coverage on shares of Cogent Biosciences in a research note on Thursday, April 27th.

https://www.dailypolitical.com/2023/06/12/cogent-biosciences-nasdaqcogt-price-target-lowered-to-27-00-at-hc-wainwright.html

#dailypolitical